Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 23

Publication Record

Connections

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar RR, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Doyle A, Ancell K, Panageas KS, Bluth M, Hedvat C, Erinjeri J, Ambrosini G, Marr B, Abramson DH, Dickson MA, Wolchok JD, Chapman PB, Schwartz GK
(2014) JAMA 311: 2397-405
MeSH Terms: Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Alkylating, Benzimidazoles, Dacarbazine, Disease Progression, Female, Humans, Male, Melanoma, Middle Aged, Survival Analysis, Temozolomide, Treatment Outcome, Uveal Neoplasms
Added June 27, 2014
0 Communities
1 Members
0 Resources
16 MeSH Terms
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O'Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A
(2014) Lancet Oncol 15: 323-32
MeSH Terms: Adult, Aged, Dacarbazine, Disease-Free Survival, Female, Follow-Up Studies, Humans, Indoles, Male, Melanoma, Middle Aged, Mutation, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Sulfonamides, Vemurafenib
Added March 20, 2014
0 Communities
1 Members
0 Resources
16 MeSH Terms
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V, Kemsley K, Dummer R
(2012) Clin Cancer Res 18: 555-67
MeSH Terms: Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Alkylating, Benzimidazoles, DNA Mutational Analysis, Dacarbazine, Disease-Free Survival, Drug Substitution, Female, Humans, Kaplan-Meier Estimate, MAP Kinase Kinase 1, MAP Kinase Kinase 2, Male, Melanoma, Middle Aged, Mutation, Neoplasm Staging, Proto-Oncogene Proteins B-raf, Proto-Oncogene Proteins p21(ras), Temozolomide, Treatment Outcome, Young Adult
Added March 20, 2014
0 Communities
1 Members
0 Resources
24 MeSH Terms
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group
(2011) N Engl J Med 364: 2507-16
MeSH Terms: Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Dacarbazine, Disease-Free Survival, Female, Humans, Indoles, Intention to Treat Analysis, Male, Melanoma, Middle Aged, Mutation, Proto-Oncogene Proteins B-raf, Sulfonamides, Survival Analysis, Vemurafenib, Young Adult
Added March 20, 2014
0 Communities
1 Members
0 Resources
19 MeSH Terms
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma.
Hersey P, Sosman J, O'Day S, Richards J, Bedikian A, Gonzalez R, Sharfman W, Weber R, Logan T, Buzoianu M, Hammershaimb L, Kirkwood JM, Etaracizumab Melanoma Study Group
(2010) Cancer 116: 1526-34
MeSH Terms: Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Dacarbazine, Disease-Free Survival, Female, Humans, Integrin alphaVbeta3, Male, Melanoma, Middle Aged, Skin Neoplasms
Added March 20, 2014
0 Communities
1 Members
0 Resources
15 MeSH Terms
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
Su Y, Amiri KI, Horton LW, Yu Y, Ayers GD, Koehler E, Kelley MC, Puzanov I, Richmond A, Sosman JA
(2010) Clin Cancer Res 16: 348-57
MeSH Terms: Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Boronic Acids, Bortezomib, Chemokines, Dacarbazine, Drug Administration Schedule, Female, Humans, Male, Melanoma, Middle Aged, NF-kappa B, Proteasome Endopeptidase Complex, Proteasome Inhibitors, Pyrazines, Skin Neoplasms, Temozolomide, Treatment Outcome
Added June 14, 2013
2 Communities
5 Members
0 Resources
20 MeSH Terms
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
Clark JI, Moon J, Hutchins LF, Sosman JA, Kast WM, Da Silva DM, Liu PY, Thompson JA, Flaherty LE, Sondak VK
(2010) Cancer 116: 424-31
MeSH Terms: Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dacarbazine, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Skin Neoplasms, Temozolomide, Thalidomide
Added March 20, 2014
0 Communities
1 Members
0 Resources
14 MeSH Terms
Dacarbazine induced acute myeloid leukemia in melanoma.
Collins CM, Morgan DS, Mosse C, Sosman J
(2009) Melanoma Res 19: 337-40
MeSH Terms: Dacarbazine, Humans, Leukemia, Myeloid, Acute, Male, Melanoma, Skin Neoplasms
Added March 20, 2014
0 Communities
1 Members
0 Resources
6 MeSH Terms
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
Yang J, Zaja-Milatovic S, Thu YM, Lee F, Smykla R, Richmond A
(2009) Mol Cancer Ther 8: 636-47
MeSH Terms: Animals, Antineoplastic Agents, Benzenesulfonates, Biomarkers, Tumor, Dacarbazine, Drug Delivery Systems, Drug Synergism, Female, Gene Expression Regulation, Neoplastic, Humans, Imidazoles, Melanoma, Mice, Mice, Inbred BALB C, Mice, Nude, Models, Biological, Niacinamide, Phenylurea Compounds, Pyridines, Quinoxalines, Skin Neoplasms, Sorafenib, Substrate Specificity, Temozolomide, Treatment Outcome, Tumor Cells, Cultured, Xenograft Model Antitumor Assays
Added June 14, 2013
2 Communities
2 Members
0 Resources
27 MeSH Terms
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.
Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM, Eastern Cooperative Oncology Group
(2008) J Clin Oncol 26: 5748-54
MeSH Terms: Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Dacarbazine, Disease-Free Survival, Female, Humans, Interferon alpha-2, Interferon-alpha, Interleukin-2, Kaplan-Meier Estimate, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Recombinant Proteins, Time Factors, Treatment Outcome, United States, Vincristine, Young Adult
Added March 20, 2014
0 Communities
1 Members
0 Resources
23 MeSH Terms